A股终于开盘，经过国庆的发酵，开盘即出现井喷。沪指高开10.13%，达到3674.4点，创业板指高开幅度高达18.44%。成交量首次突破三万亿，达到3.45万亿的历史巨量，上涨股票超5000只，市场呈现一片牛市欣欣向荣景象。而港股这边画风突变，直接低 ...

Viridian Therapeutics (VRDN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Piper Sandler维持Acelyrin Inc (NASDAQ: SLRN)的"增持"评级和20.00美元的目标价。 该公司的立场是在预期2024年底或2025年初将获得lonigutamab的进一步Phase 1/2数据。 根据Acelyrin的管理团队表示，最近的ESOPRS数据突显了lonigutamab对甲状腺眼病 (TED)患者生活质量的显著影响。

4 It often occurs in people living with Graves' disease, but is a distinct disease that is caused by autoantibodies ...

“Fashion continues to turn against hatches so the 1 Series range has shrunk. But if a petrol auto suits you this is a fine car” It's one of the most satisfying compact hatches around. Much ...

相关研究结果发表在2024年9月9日的Cancer Cell期刊上，论文标题为“Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence”。 这项研究由路德维格 ...

With potential to have lonigutamab as a possible best-in-class anti-IGF-1R drug for TED, plus moving rapidly into phase 3 clinical testing, I believe that investors could benefit with any ...

VRDN-001 is also IV administered and is a monoclonal antibody, but also acts as a full antagonist of the IGF-1R signaling pathway. This should provide it with some advantages over Tepezza (above).

Gametogenesis involves active protein synthesis and is proposed to rely on proteostasis. Our previous work in C. elegans indicates that germline development requires coordinated activities of ...

后续管线包括CTLA-4融合蛋白、TNFα抗体、C1s抗体、IGF-1R抗体等。 “近两年，泽纳仕在IgG4-RD这一罕见病治疗领域取得了稳健且突出的进展，近期的同靶 ...